证券代码：603858 证券简称：步长制药 公告编号：2025-232 山东步长制药股份有限公司 关于拟向控股子公司增资的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 2025 年 10 月 29 日，山东步长制药股份有限公司（以下简称"公司"或"步 长制药"）召开第五届董事会第三十四次会议，审议通过了《关于拟增资济南步 长晟源医疗器械有限公司的议案》，公司拟与济南步长晟源医疗器械有限公司（以 下简称"步长晟源医疗"）其他股东按照现有持股比例，按 1 元/股的价格以现金 方式向步长晟源医疗合计增资 300 万元人民币。本次增资完成后，步长晟源医疗 的注册资本将由 1,000 万元人民币增加至 1,300 万元人民币。具体内容详见公司 2025 年 10 月 30 日披露于上海证券交易所网站（www.sse.com.cn）的《关于拟 向控股子公司增资的公告》（公告编号：2025-204）。 乙方五：徐伟 丙方：济南步长晟源医疗器械有限公司 以上各方合称"各方"，单称"一方"。 2、增资 （1）截至 20 ...

步长制药公告称，公司于2025年12月12日与有关各方签署《关于济南步长晟源医疗器械有限公司之增资 协议》等。公司拟与其他股东按现有持股比例，以1元/股的价格向步长晟源医疗合计增资300万元，其 中公司出资270万元。增资完成后，其注册资本将由1000万元增至1300万元，公司持股比例为90%。各 方同意在协议生效后20个工作日内完成工商变更登记，公司及其他股东将在登记完成后5年内支付增资 款。本次增资将提升子公司竞争力，对公司长远发展有积极影响。 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-231 山东步长制药股份有限公司 关于为公司控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、担保情况概述 山东步长制药股份有限公司（以下简称"公司"或"步长制药"）于 2021 年12月22日与中信银行股份有限公司成都分行（以下简称"中信银行成都分行"） 签订《最高额保证合同》，为公司控股子公司四川泸州步长生物制药有限公司（以 下简称"泸州步长"）于 2021 年 12 月 22 日至 2028 年 11 月 19 日期间与中信银 行成都分行签订的主合同（包括借新还旧、展期、变更还款计划、还旧借新等债 务重组业务合同）提供最高额 35,000 万元连带责任担保。具体内容详见公司于 2021 年 12 月 24 日披露于上海证券交易所网站（www.sse.com.cn）的《关于为 全资子公司提供担保的公告》（公告编号：2021-162）。 二、本次担保的进展 近日，根据泸州步长实际经营现状，公司与中信银行成都分行经充分协商， 在原《 ...

Core Viewpoint - The announcement from the Shaanxi Provincial Drug Administration details the results of GMP compliance inspections for three pharmaceutical companies, indicating varying levels of compliance with regulatory standards [2] Group 1: Company Compliance Results - Shaanxi Buchang Pharmaceutical Co., Ltd. was found to be compliant with GMP requirements during inspections conducted from September 16 to September 19, 2025, covering tablet production lines [2] - Xi'an Boai Pharmaceutical Co., Ltd. was found to be non-compliant with GMP requirements during inspections conducted from October 13 to October 17, 2025, focusing on raw material production lines [2] - Shaanxi Fujie Pharmaceutical Co., Ltd. was found to be compliant with GMP requirements during inspections conducted from October 28 to November 1, 2025, covering multiple production lines for raw materials [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603858 证券简称：步长制药 公告编号：2025-230 山东步长制药股份有限公司关于控股子公司拟对外投资设立子公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 投资标的名称：珠海大阡陌步长医药科技有限公司（暂定名，最终名称以工商部门核准登记为准） ● 投资金额：珠海大阡陌步长医药科技有限公司注册资本为100万元，公司控股子公司步长金钥匙出资 人民币51万元，持股比例为51%。 1、本次交易概况 山东步长金钥匙医药科技有限公司（以下简称"步长金钥匙"）为山东步长制药股份有限公司（以下简 称"公司"）的控股子公司。根据公司总体发展规划，为促进步长金钥匙经营发展，步长金钥匙拟对外投 资51万元，与尹卫群共同投资设立一家新公司。 2、本次交易的交易要素 ■ （二）审议情况 公司于2025年12月3日发出第五届董事会第三十八次会议的通知，并于2025年12月10日13时以通讯方式 召开，会议以同意12票、反对0票、弃权0票的表决结果审议通过了 ...

山东步长制药股份有限公司 关于控股子公司拟对外投资设立子公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603858 证券简称：步长制药 公告编号：2025-230 山东步长金钥匙医药科技有限公司（以下简称"步长金钥匙"）为山东步长 制药股份有限公司（以下简称"公司"）的控股子公司。根据公司总体发展规划， 为促进步长金钥匙经营发展，步长金钥匙拟对外投资 51 万元，与尹卫群共同投 资设立一家新公司。 2、本次交易的交易要素 重要内容提示： 投资标的名称：珠海大阡陌步长医药科技有限公司（暂定名，最终名称以工 商部门核准登记为准） 投资金额：珠海大阡陌步长医药科技有限公司注册资本为 100 万元，公司控 股子公司步长金钥匙出资人民币 51 万元，持股比例为 51%。 交易实施尚需履行的审批及其他相关程序：本次交易未达到股东会审议标 准,无需提交股东会审议。 相关风险提示：新公司设立后，在实际经营过程中可能受到宏观政策调控、 市场变化及经营管理等因素影响，后续投资收益存在一定的不确定性，公司 将积极采取适当的策 ...

财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：安东 格隆汇12月10日丨步长制药(603858.SH)公布，山东步长金钥匙医药科技有限公司（以下简称"步长金钥 匙"）为公司的控股子公司。根据公司总体发展规划，为促进步长金钥匙经营发展，步长金钥匙拟对外 投资51万元，与尹卫群共同投资设立一家新公司。 本次投资标的为珠海大阡陌步长医药科技有限公司（暂定名，最终名称以工商部门核准登记为准）。注 册资本为100万元，公司控股子公司步长金钥匙出资51万元，持股比例为51%，尹卫群出资49万元，持 股比例为49%。 ...

步长制药公告，控股子公司步长金钥匙拟与尹卫群共同投资设立珠海大阡陌步长医药科技有限公司，注 册资本为100万元。步长金钥匙出资人民币51万元，持股比例为51%。新公司设立后，可能受到宏观政 策调控、市场变化及经营管理等因素影响，后续投资收益存在不确定性。 ...

Core Viewpoint - The recognition of "Annual Drug R&D Innovation Enterprise" and "Annual Excellent Public Welfare Enterprise" awarded to the company reflects its dual leadership in industry innovation and social responsibility, serving as a model for sustainable development in the pharmaceutical sector [1][4][13]. Group 1: Innovation and R&D - The company has been awarded "Annual Drug R&D Innovation Enterprise" due to its over 30 years of dedication to the pharmaceutical industry, with innovation as its core development engine [6]. - In 2018, the company announced a strategic transformation from a marketing-driven model to a product and technology-driven approach, expanding from traditional Chinese medicine to biopharmaceuticals, chemical drugs, medical devices, and internet medicine [6]. - The R&D investment reached 717 million yuan in 2024, an increase of 8.58% year-on-year, emphasizing the importance of continuous investment in innovation [6]. - As of mid-2025, the company holds 457 valid patents and has over 200 products under development, establishing a solid foundation for industry innovation [7]. - The company’s flagship products, including "Nerve and Heart Capsule," "Stable Heart Granule," and "Dan Hong Injection," generated a total sales revenue of 5.83 billion yuan in 2024, with a market share ranking in the top five for cardiovascular traditional Chinese medicine [7][8]. Group 2: Social Responsibility and Public Welfare - The company has been recognized as "Annual Excellent Public Welfare Enterprise" for its commitment to social responsibility, integrating public welfare into its core business [10][11]. - The "Together to Build a Chinese Heart" public welfare project has been ongoing for 18 years, benefiting over 1 million people in Tibetan regions through medical support and health initiatives [11][12]. - The company’s public welfare efforts are not merely financial donations but involve deep collaboration with its business strategy, enhancing both social impact and corporate value [12]. - Since its establishment, the company has contributed nearly 33 billion yuan in taxes, supporting local economic development [12]. Group 3: Future Outlook - The dual recognition of "Annual Drug R&D Innovation Enterprise" and "Annual Excellent Public Welfare Enterprise" exemplifies the company's successful "innovation + public welfare" dual-driven development model [13]. - The company aims to deepen its global layout and continue breakthroughs in biopharmaceuticals and vaccines, while expanding its public welfare projects, contributing to the "Healthy China" strategy and high-quality development of the pharmaceutical industry [13].

Core Insights - The company, Buchang Pharma, has been awarded "Annual Drug R&D Innovation Enterprise" and "Annual Excellent Public Welfare Enterprise" at the 2025 9th Century Health Industry Competitiveness Research "Sunshine" Case, highlighting its dual leadership in drug innovation and social responsibility [1][6] Group 1: Innovation and R&D - Buchang Pharma's recognition as "Annual Drug R&D Innovation Enterprise" is a result of over 30 years of commitment to the pharmaceutical industry, with innovation as its core development engine [2] - The company announced a strategic transformation in 2018, shifting from a marketing-driven model to a product and technology-driven approach, expanding from traditional Chinese medicine to biopharmaceuticals, chemical drugs, and medical devices [2] - In 2024, the company's R&D investment reached 717 million yuan, an increase of 8.58% year-on-year, with a focus on both independent innovation and collaborative research [2] - As of mid-2025, Buchang Pharma holds 457 valid patents and has over 200 products in development, laying a solid foundation for industry-wide innovation [2] Group 2: Product Portfolio - The company has established a product portfolio that covers major disease areas, including cardiovascular, gynecological, urological, diabetes, and oncology [3] - Key proprietary products, including Naoxin Tong Capsule, Stabilizing Heart Granules, and Danhong Injection, generated sales of 5.83 billion yuan in 2024 and 3.12 billion yuan in the first half of 2025, ranking in the top five in the cardiovascular traditional Chinese medicine market [3] - These key products are included in the 2024 National Medical Insurance Directory, ensuring reimbursement support and facilitating market share expansion [3] Group 3: Social Responsibility and Public Welfare - The company has been actively engaged in public welfare for over 20 years, focusing on social responsibility as a core component of its business strategy [6] - The "Together to Build a Chinese Heart" project has provided assistance to over 100 million people in Tibetan and other underdeveloped regions, showcasing the company's commitment to healthcare and community support [6][7] - Buchang Pharma's public welfare initiatives are integrated with its business strategy, enhancing brand recognition and expanding market reach while addressing healthcare needs in underserved areas [8] - Since its establishment, the company has contributed nearly 33 billion yuan in taxes, supporting local economic development [8]